Novo Nordisk's biopharm arm recedes in Q3

Although the division has progressed during the first nine months of the year as a whole, this is not true of the third quarter of the year, where the pharmaceutical company reports a slight regression.

Photo: Novo Nordisk / PR

The biopharm division at Novo Nordisk could not live up to the progress achieved in the first 6 months of 2021 during Q3.

In its quarterly report, the pharmaceutical company reveals that the segment has brought in DKK 4.5bn (USD 700m), equating to a small regression of 2 percent. This comes after a drop in sales on the North American, European and Middle Eastern markets, which has undermined the positive developments in the rest of the world, for example in China, where the business arm is still new, and relatively small, but experiencing explosive growth. This market has provided DKK 121m (USD 18.8m) in sales so far this year, double that of the sales revenue for the same period last year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs